RIDR-PI-103, ROS-activated prodrug PI3K inhibitor inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor-resistant BRAF-mutant melanoma cells
Hima Patel(Kansas City University), Joan T. Garrett(University of Cincinnati Medical Center)
Cited by 6
Related Papers
Current Advances in the Treatment of BRAF-Mutant Melanoma
|Cancers|2020|172
Activating HER3 mutations in breast cancer
|Oncotarget|2018|36